LABORATORY NEWS
-
Bionano Laboratories Announces Expansion Of Diagnostic Testing Based On Optical Genome Mapping For Hematologic Malignancies
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced expansion of optical genome mapping (OGM) based testing of hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK), following approval from the New York State Department of Health (NYSDOH).
- Mayo Clinic Laboratories Invests In Pathology Asia Holdings And LifeStrands Genomics To Advance Diagnostics And Precision Medicine
- BioEdge Research Labs Announces Quality-Control Measures For Research Materials
- RealTime Laboratories Launches 31-Marker Mycotoxin Extensive Panel, The Most Comprehensive Urinary Mycotoxin Test On The Market
- UK Digital Pathology Provider Source BioScience Chooses Sectra To Enable Seamless Pathology Collaboration Across The NHS
ARCHIVED NEWSLETTER
- 09.22.26 -- Sakura Finetek Europe Launches Sakura Pathology Network
- 08.25.26 -- GHK-Cu Peptide Launched By Kylo Peptides For Laboratory Research Applications
- 07.21.26 -- Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches
- 07.07.26 -- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
- 05.26.26 -- Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics